Alzheimer’s monoclonal antibodies fail to deliver meaningful results
Despite reducing amyloid plaques, antibody treatments for Alzheimer’s fail to improve cognition, highlighting critical gaps in current therapeutic approaches.
Despite reducing amyloid plaques, antibody treatments for Alzheimer’s fail to improve cognition, highlighting critical gaps in current therapeutic approaches.